Mantis Biotech vs Oura

Side-by-side comparison of AI visibility scores, market position, and capabilities

Mantis Biotech

EmergingBioTech

AI Clinical Trial Simulation

Raised $48M Series A led by a16z Bio and GV (Feb 2026). YC-backed. Digital twins of human physiology to generate diverse synthetic trial data.

About

Mantis Biotech is a YC-backed AI company that builds digital twins of human physiology to synthesize diverse, realistic clinical trial populations. The company addresses one of drug development's most persistent problems: clinical trials consistently underrepresent women, elderly patients, and minorities, producing efficacy data that fails to predict real-world outcomes across populations. Mantis's AI platform generates synthetic patient data that fills these representation gaps.

Full profile

Oura

LeaderConsumer Tech

Smart Health Wearables

Raised $900M Series E at $11B valuation (Oct 2025). CEO projects ~$2B in 2026 sales. Launched women's health LLM (Feb 2026). Team USA LA28 Olympic partner.

About

Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E financing at an $11 billion valuation in October 2025, reflecting the doubling of its revenue to $500 million in 2024 and a projected $1.5–2 billion in 2026 sales as it expands global distribution into India, UAE, and Latin America.

Full profile

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.